EGFRvIII Peptide

A synthetic peptide sequence derived from the tumor specific mutant variant of epidermal growth factor receptor EGFRvIII originally found in glioblastoma multiforme, caused by the deletion of exons 2-7. Unlike wild-type EGFR, EGFRvIII is a dominant oncogene that can directly lead to cancer. EGFRvIII is expressed in multiple cancer types including breast, ovarian, and metastatic prostate cancers, and other types of solid tumors due to alternative splicing; has not been observed in normal human tissues. Vaccination with EGFRvIII peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for EGFRvIII, resulting in decreased tumor growth. (NCI Thesaurus)

YOU MAY ALSO LIKE

EGFRBi-Armed Autologous T Cells

Autologous activated T cells, loaded with a bispecific antibody produced by heteroconjugation of anti-CD3 and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies,…

EGFR/HER2 Kinase Inhibitor TAK-285

An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with potential…

EGFR/HER2 Inhibitor AV-412

A second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor…

EGFR-TKI Sensitizing Mutation

A molecular genetic abnormality indicating the presence of a sensitizing mutation in the epidermal growth factor receptor-tyrosine kinase inhibitor domain.

EGFR-TKI Resistant Mutation

A molecular genetic abnormality indicating the presence of resistance in the epidermal growth factor receptor-tyrosine kinase inhibitor domain, due to secondary mutations…

EGFR wt Allele

Human EGFR wild-type allele is located within 7p12 and is approximately 188 kb in length. This allele, which encodes epidermal growth factor…